For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?

The standard of care for metastatic endometrial cancer is systemic therapy with chemotherapy and now with or without immunotherapy. With this approach to therapy, there is a roughly 70% reduction in the risk of progression or death across three separate trials for the dMMR population (RUBY, GY018, A...

The addition of immunotherapy to chemotherapy should certainly be considered the standard of care for patients with dMMR tumors. At the 2023 ESMO meeting, Dr. @Dr. First Last and team made a compelling argument to further strengthen the use of immunotherapy in the front line. Using the RUBY patient ...